



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BR2082c : Breast disease spectrum (breast cancer progression) tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 186 cases/192 cores, replacing BR2082b

Microarray Panel	Breast disease spectrum tissue microarray, containing 32 cases of metastatic carcinoma, 69 invasive carcinoma of no special type, 21 lobular carcinoma, 4 squamous cell carcinoma, 17 ductal carcinoma in situ, 1 intraductal papillary carcinoma, 7 fibroadenoma, 6 hyperplasia, 15 inflammation, 7 adjacent normal breast tissue, 12 cancer adjacent breast tissue, 1 breast tissue, single core per block	
Cores	192	
Cases	186	
Row number	12	
Column number	16	
Core Diameter (mm)	1	
Thickness (µm)	5	
Quality Control	H&E and IHC confirmed	
Tissue Array Type	FFPE	
Species	Human	
Notes	<p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheet, "" means invalid core; "-" means no applicable or negative in IHC markers.</p>	



Legend: Bre - Breast, Lym - Lymph node
 ● - AT, ● - Benign tumor, ● - Hyperplasia, ● - Inflammation, ● - Malignant tumor (stage 0), ● - Malignant tumor (stage IA), ● - Malignant tumor (stage IB), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIB), ● - Metastasis, ● - NAT, ● - Normal tissue

tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	ER	PR	HER2	Ki67	Image
A1	1	40	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	3+	+, 10%	
A2	2	55	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	+	0	+, 3%	
A3	3	56	F	Lymph node	Metastatic carcinoma from breast with necrosi	-	-	-	Metastasis	+++	+	0	+, 15%	
A4	4	43	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	3+	+3%	
A5	5	38	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	++	0	+20%	
A6	6	56	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	3+	+, 5%	
A7	7	66	F	Lymph node	Metastatic carcinoma from breast	-	*	-	Metastasis	++	+	2+	+, 15%	
A8	8	55	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	0	+, 3%	
A9	9	44	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	+++	0	+, 20%	
A10	10	56	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+	-	0	+, 15%	
A11	11	51	F	Lymph node	Metastatic carcinoma from breast	-	*	-	Metastasis	+++	++	0	+, 20%	
A12	12	40	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	++	1+	+, 10%	
A13	13	53	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	3+	+, 10%	
A14	14	42	F	Lymph node	Metastatic carcinoma from breast (sparse)	-	-	-	Metastasis	-	-	3+	+, 5%	
A15	15	38	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	0	+, 10%	
A16	16	39	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	++	++	0	+, 5%	
B1	17	52	F	Lymph node	Metastatic carcinoma from breast of No.44	-	2	-	Metastasis	+++	+	3+	+, 15%	
B2	18	28	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	3+	+, 30%	
B3	19	80	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	++	-	3+	+, 3%	
B4	20	58	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	+++	0	+, 3%	
B5	21	42	F	Lymph node	Metastatic carcinoma from breast	-	3	-	Metastasis	++	+	0	-	
B6	22	49	F	Lymph node	Metastatic carcinoma from breast	-	3	-	Metastasis	-	-	3+	+, 3%	
B7	23	54	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	++	+	2+	+, 3%	
B8	24	62	F	Lymph node	Metastatic carcinoma from breast	-	3	-	Metastasis	+	-	0	+, 15%	
B9	25	39	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	+++	2+	-	
B10	26	49	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	-	0	+, 65%	
B11	27	59	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	+++	+	3+	+, 20%	
B12	28	54	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	++	-	2+	+, 3%	
B13	29	45	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	1+	+, 3%	
B14	30	46	F	Lymph node	Metastatic carcinoma from breast	-	3	-	Metastasis	-	-	0	+, 70%	
B15	31	60	F	Lymph node	Metastatic carcinoma from breast	-	2	-	Metastasis	-	-	3+	+, 65%	
B16	32	52	F	Lymph node	Metastatic carcinoma from breast	-	3	-	Metastasis	+++	-	3+	+, 3%	
C1	33	46	F	Breast	Invasive carcinoma of no special type	T3N0M0	2	IIB	Malignant	+++	+++	0	+, 5%	
C2	34	59	F	Breast	Invasive carcinoma of no special type	T1N0M0	2	IA	Malignant	-	-	3+	+5%	
C3	35	29	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	+	0	+, 3%	

C4	36	55	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+++	+	0	+, 15%
C5	37	30	F	Breast	Invasive carcinoma of no special type	T2N2M0	2	IIIA	Malignant	-	-	3+	+, 20%
C6	38	64	F	Breast	Invasive carcinoma of no special type (spars e)	T2N0M0	1	IIA	Malignant	+++	++	0	+, 3%
C7	39	54	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	++	1+	+, 1%
C8	40	30	F	Breast	Invasive carcinoma of no special type	1cN0M0	1	IA	Malignant	+++	+++	0	+, 3%
C9	41	67	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	-	0	+, 5%
C10	42	50	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	+++	+++	0	+, 5%
C11	43	62	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	-	-	3+	+, 1%
C12	44	52	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	+++	-	3+	+, 20%
C13	45	47	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	+	+	3+	+, 10%
C14	46	43	F	Breast	Invasive carcinoma of no special type	T1N0M0	*	IA	Malignant	+++	+++	0	+, 3%
C15	47	41	F	Breast	Invasive carcinoma of no special type	T3N2M0	2	IIIA	Malignant	+	-	0	-
C16	48	46	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+	-	3+	+, 15%
D1	49	42	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	-	-	0	+, 90%
D2	50	53	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	+++	-	0	+, 50%
D3	51	68	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+++	+++	0	+, 3%
D4	52	53	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+++	-	3+	+, 3%
D5	53	50	F	Breast	Invasive carcinoma of no special type	T2N1M0	1	IIB	Malignant	++	++	2+	+, 1%
D6	54	48	F	Breast	Invasive carcinoma of no special type	T4N2M0	2	IIIB	Malignant	++	+++	0	+, 3%
D7	55	44	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	+++	0	+, 10%
D8	56	63	F	Breast	Invasive carcinoma of no special type	T3N0M0	1	IIB	Malignant	+++	-	2+	+, 1%
D9	57	45	F	Breast	Invasive carcinoma of no special type	T1N0M0	2	IA	Malignant	-	-	0	+, 1%
D10	58	32	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+++	+++	0	+, 5%
D11	59	52	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	+++	++	0	-
D12	60	53	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	-	-	3+	+, 20%
D13	61	42	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+++	+++	0	+, 3%
D14	62	44	F	Breast	Invasive carcinoma of no special type	T1N0M0	2	IA	Malignant	+++	+++	0	+, 3%
D15	63	48	F	Breast	Invasive carcinoma of no special type	T2M0N0	2	IIA	Malignant	+++	-	2+	+, 3%
D16	64	72	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	-	-	3+	+, 5%
E1	65	54	F	Breast	Invasive carcinoma of no special type	T1N0M0	2	IA	Malignant	+++	++	3+	+, 15%
E2	66	29	F	Breast	Invasive carcinoma of no special type	T2M0N0	2	IIA	Malignant	-	-	3+	+, 15%
E3	67	48	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	+++	+++	0	+, 10%
E4	68	65	F	Breast	Invasive carcinoma of no special type	T1N2M0	2	IIIA	Malignant	-	-	0	+, 10%
E5	69	38	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+	++	0	+, 10%
E6	70	35	F	Breast	Invasive carcinoma of no special type	T1N0M0	2	IA	Malignant	++	++	3+	+, 20%
E7	71	29	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	-	-	3+	+, 5%
E8	72	38	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	-	-	3+	+, 5%
E9	73	50	F	Breast	Invasive carcinoma of no special type	T2N2M0	2	IIIA	Malignant	-	-	3+	-
E10	74	55	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	++	-	3+	+, 5%
E11	75	45	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+	++	0	+, 3%
E12	76	43	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	+++	+++	0	+, 5%
E13	77	45	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	-	-	0	+, 50%
E14	78	45	F	Breast	Invasive carcinoma of no special type	T3N1M0	2	IIIA	Malignant	+++	+	3+	+, 5%
E15	79	28	F	Breast	Invasive carcinoma of no special type	T1N0M0	3	IB	Malignant	-	-	3+	+, 5%
E16	80	45	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	+++	0	+, 30%
F1	81	63	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	+++	0	+, 10%
F2	82	65	F	Breast	Invasive carcinoma of no special type	T2N0M0	1	IIA	Malignant	+++	+++	2+	+, 3%
F3	83	71	F	Breast	Invasive carcinoma of no special type	T2N2M0	3	IIIA	Malignant	+++	++	0	+, 5%
F4	84	52	F	Breast	Invasive carcinoma of no special type	T2N1M0	3	IIB	Malignant	++	-	+	+, 5%
F5	85	49	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	-	-	3+	+, 10%
F6	86	45	F	Breast	Invasive carcinoma of no special type	T2M0N0	*	IIA	Malignant	-	-	0	+, 15%
F7	87	38	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	+++	+++	0	+, 10%
F8	88	63	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	+++	++	0	+, 30%
F9	89	47	F	Breast	Invasive carcinoma of no special type	T2N1M0	3	IIB	Malignant	++	+++	2+	+, 50%
F10	90	37	F	Breast	Invasive carcinoma of no special type	T2N1M0	3	IIB	Malignant	-	-	0	+, 10%
F11	91	46	F	Breast	Invasive carcinoma of no special type	T3N1M0	3	IIIA	Malignant	-	-	2+	+, 3%
F12	92	58	F	Breast	Invasive carcinoma of no special type	T3N1M0	3	IIIA	Malignant	++	-	0	+, 3%
F13	93	62	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	-	-	0	+, 30%
F14	94	50	F	Breast	Invasive carcinoma of no special type	T3N2M0	3	IIIA	Malignant	-	-	2+	+, 55%
F15	95	55	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	-	-	0	+, 75%
F16	96	45	F	Breast	Invasive carcinoma of no special type	T3N0M0	3	IIB	Malignant	+++	-	3+	+, 5%
G1	97	56	F	Breast	Invasive carcinoma of no special type	T2N1M0	1	IIB	Malignant	-	-	0	+, 5%
G2	98	48	F	Breast	Invasive carcinoma of no special type	T2N2M0	1	IIIA	Malignant	-	-	3+	-
G3	99	42	F	Breast	Invasive carcinoma of no special type	T2N1M0	1	IIB	Malignant	+++	-	2+	+, 8%
G4	100	47	F	Breast	Invasive carcinoma of no special type	T4N0M0	1	IIIB	Malignant	-	-	0	-
G5	101	54	F	Breast	Invasive carcinoma of no special type	T3N0M0	1	IIB	Malignant	-	-	3+	+, 3%
G6	102	55	F	Breast	Invasive lobular carcinoma	T2N2M0	-	IIIA	Malignant	+	-	3+	-
G7	103	45	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	+++	+++	0	+, 3%
G8	104	51	F	Breast	Invasive lobular carcinoma	T2N1M0	*	IIB	Malignant	*	*	*	*
G9	105	69	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	+	-	0	-
G10	106	54	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	++	+	0	-
G11	107	59	F	Breast	Invasive lobular carcinoma	T4N0M0	-	IIIB	Malignant	+++	+++	0	+, 5%
G12	108	70	F	Breast	Invasive lobular carcinoma	T4N0M0	-	IIIB	Malignant	++	-	0	-
G13	109	38	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	+++	+++	0	+, 10%
G14	110	42	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	-	-	0	-
G15	111	47	F	Breast	Invasive lobular carcinoma	T4N0M0	-	IIIB	Malignant	+++	++	0	+, 8%
G16	112	41	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	++	++	0	+, 15%
H1	113	19	F	Breast	Invasive lobular carcinoma	T2N1M0	*	IIB	Malignant	++	+	0	-
H2	114	40	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	++	+	0	+, 3%
H3	115	52	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	-	-	0	+, 10%
H4	116	59	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	+	+	0	-
H5	117	55	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	+++	+	2+	+, 5%
H6	118	50	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	-	-	0	-
H7	119	45	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	+++	+++	1+	+, 3%
H8	120	44	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	+++	++	0	+, 5%
H9	121	59	F	Breast	Invasive lobular carcinoma	T2N0M0	-	IIA	Malignant	+	-	3+	+, 10%

H10	122	45	F	Breast	Invasive lobular carcinoma	T2N1M0	-	IIB	Malignant	+++	-	2+	+, 15%
H11	123	48	F	Breast	Squamous cell carcinoma	T4N0M0	1	IIIB	Malignant	-	-	1+	+, 15%
H12	124	37	F	Breast	Squamous cell carcinoma	T3N0M0	2	IIB	Malignant	-	-	3+	+, 25%
H13	125	44	F	Breast	Squamous cell carcinoma	T1N0M0	2	IB	Malignant	-	-	0	+, 10%
H14	126	47	F	Breast	Squamous cell carcinoma	T1N0M0	3	IA	Malignant	-	-	3+	+, 5%
H15	127	36	F	Breast	Ductal carcinoma in situ with invasion	TisN0M0	*	0	Malignant	+++	+++	0	+, 5%
H16	128	62	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	-	-	3+	+, 5%
I1	129	54	F	Breast	Intraductal papillary carcinoma	TisN0M0	-	0	Malignant	+++	++	0	+, 1%
I2	130	43	F	Breast	Ductal carcinoma in situ(breast tissue)	TisN0M0	*	0	Malignant	+	+	0	+, 1%
I3	131	49	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+	+	0	+, 2%
I4	132	45	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	+++	0	+, 5%
I5	133	46	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	+++	0	+, 5%
I6	134	45	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	-	-	2+	+, 3%
I7	135	39	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	-	-	3+	+, 10%
I8	136	55	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	++	0	-
I9	137	47	F	Breast	Ductal carcinoma in situ (fibrous tissue)	TisN0M0	-	0	Malignant	*	*	*	*
I10	138	63	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	+++	2+	+, 5%
I11	139	47	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	+++	0	+, 5%
I12	140	48	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	+++	0	+, 3%
I13	141	41	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	-	-	3+	+, 3%
I14	142	55	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	-	-	3+	+, 5%
I15	143	47	F	Breast	Ductal carcinoma in situ (sparse)	TisN0M0	-	0	Malignant	-	-	0	-
I16	144	51	F	Breast	Ductal carcinoma in situ	TisN0M0	-	0	Malignant	+++	+++	0	-
J1	145	36	F	Breast	Fibroadenoma	-	-	-	Benign	+	++	0	-
J2	146	34	F	Breast	Fibroadenoma	-	-	-	Benign	+++	++	0	-
J3	147	25	F	Breast	Fibroadenoma	-	-	-	Benign	+++	++	0	-
J4	148	23	F	Breast	Fibroadenoma	-	-	-	Benign	+++	++	0	-
J5	149	44	F	Breast	Adenosis	-	-	-	Inflammation	++	++	0	-
J6	150	27	F	Breast	Adenosis	-	-	-	Inflammation	++	++	0	+, 8%
J7	151	23	F	Breast	Fibroadenoma	-	-	-	Benign	+++	++	0	+, 1%
J8	152	45	F	Breast	Fibroadenoma	-	-	-	Benign	++	+++	0	+, 10%
J9	153	19	F	Breast	Fibroadenoma	-	-	-	benign	++	++	0	+, 1%
J10	154	45	F	Breast	Adenosis	-	-	-	Inflammation	++	++	0	-
J11	155	45	F	Breast	Simple hyperplasia of duct epithelium (fibrous tissue)	-	-	-	Hyperplasia	*	*	*	-
J12	156	46	F	Breast	Adjacent normal breast tissue (sparse)	-	-	-	NAT	++	++	0	-
J13	157	48	F	Breast	Mild atypical hyperplasia of duct	-	-	-	Hyperplasia	+++	++	0	-
J14	158	82	F	Breast	Hyperplasia	-	-	-	Hyperplasia	+	++	0	-
J15	159	38	F	Breast	Hyperplasia	-	-	-	Hyperplasia	++	++	0	-
J16	160	40	F	Breast	Mild atypical hyperplasia of duct	-	-	-	Hyperplasia	+++	+++	0	+, 1%
K1	161	37	F	Breast	Ductal papillomatosis with hyperplasia	-	-	-	Hyperplasia	++	+	0	+, 3%
K2	162	32	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	-	-	0	-
K3	163	46	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	+	+	0	-
K4	164	55	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	*	*	*	*
K5	165	39	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	++	++	0	-
K6	166	39	F	Breast	Chronic mastitis No.135	-	*	-	Inflammation	++	++	0	-
K7	167	29	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	*	*	*	*
K8	168	42	F	Breast	Acute mastitis	-	-	-	Inflammation	++	-	0	-
K9	169	35	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	-	-	0	-
K10	170	41	F	Breast	Plasma cell mastitis	-	-	-	Inflammation	+	+	0	-
K11	171	44	F	Breast	Chronic mastitis	-	-	-	Inflammation	+	+	0	-
K12	172	43	F	Breast	Plasma cell mastitis with acute infalmmation	-	-	-	Inflammation	-	-	0	-
K13	173	29	F	Breast	Chronic mastitis of No.66	-	-	-	Inflammation	+	+	0	+, 1%
K14	174	53	F	Breast	Cancer adjacent breast tissue	-	*	-	AT	+	+	0	+, 3%
K15	175	49	F	Breast	Cancer adjacent breast tissue (chronic mastitis)	-	-	-	AT	+	+	0	-
K16	176	44	F	Breast	Adjacent normal breast tissue (adenosis) of No.9	-	-	-	NAT	+	+	0	-
L1	177	48	F	Breast	Cancer adjacent breast tissue of No.140	-	-	-	AT	+	+	0	-
L2	178	40	F	Breast	Cancer adjacent breast tissue (fibrous tissue)	-	-	-	AT	*	*	*	*
L3	179	36	F	Breast	Cancer adjacent breast tissue (fibrous tissue)	-	*	-	AT	*	*	*	*
L4	180	42	F	Breast	Cancer adjacent breast tissue	-	*	-	AT	+	+	0	-
L5	181	55	F	Breast	Adjacent normal breast tissue of No.117	-	-	-	NAT	+	*	*	*
L6	182	57	F	Breast	Cancer adjacent breast tissue	-	*	-	AT	+	+	0	-
L7	183	46	F	Breast	Cancer adjacent breast tissue	-	-	-	AT	+	+	0	+, 1%
L8	184	35	F	Breast	Adjacent normal breast tissue	-	-	-	NAT	+	+	0	-
L9	185	47	F	Breast	Cancer adjacent breast tissue(fibrous tissue)	-	-	-	AT	*	*	*	*
L10	186	45	F	Breast	Cancer adjacent breast tissue	-	-	-	AT	+	+	0	-
L11	187	55	F	Breast	Adjacent normal breast tissue	-	-	-	NAT	+	+	0	-
L12	188	42	F	Breast	Adjacent normal breast tissue	-	-	-	NAT	+	+	0	-
L13	189	48	F	Breast	Cancer adjacent breast tissue	-	*	-	AT	*	*	*	*
L14	190	50	F	Breast	Cancer adjacent breast tissue	-	-	-	AT	+	+	0	+, 3%
L15	191	41	F	Breast	Adjacent normal breast tissue	-	*	-	NAT	++	++	0	+, 3%
L16	192	21	F	Breast	Breast tissue	-	-	-	Normal	+	+	0	+, 3%

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC
USA & Canada 
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV
EU 
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd
UK & Rest of the World 
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd
Switzerland 
Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV
Deutschland 
T: +49 (0) 69 779099
F: +49 (0) 69 13376880